Jingjia reports 2022 H1 revenue increase

Aug.22.2022
Jingjia reports 2022 H1 revenue increase
Jinjia achieved revenue growth despite challenges in the tobacco business, with promising growth in the new tobacco industry.

Jingtian & Gongcheng, a company listed on the Shenzhen Stock Exchange under the symbol 002191.SZ, has released its H1 2022 financial report. The report shows that the company has achieved operating revenue of CNY 2.644 billion, an increase of 8.03% year-on-year. The net profit attributable to shareholders of the listed company amounted to CNY 500 million, a decrease of 1.40% year-on-year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses amounted to CNY 425 million, a decrease of 11.29% year-on-year. The basic earnings per share is CNY 0.34/share.


During the reporting period, the revenue from cigarette label products decreased by 9.56% compared to the same period last year. The company's cigarette label business experienced some fluctuations due to factors such as intensified regional market competition, decreased bidding prices, fluctuating production raw material costs, and sporadic COVID-19 outbreaks.


During the reporting period, the company achieved a 297.53% increase in revenue from its new tobacco business compared to the same period last year. The company has been actively adapting to new regulations surrounding electronic cigarettes, streamlining and optimizing the mechanism and processes of cooperation among the entities in its new tobacco industry chain. This strategy has effectively leveraged the company's resources, resulting in overall positive growth in areas such as technology research and development, new product development, and customer collaboration. As such, the company has been able to successfully implement high-quality strategies for advancing its new tobacco development plans.


This article contains excerpts or reprints of third-party information. The copyright belongs to the original media and author. If there is any infringement, please contact us for deletion. Any organization or individual who wishes to reproduce this content should contact the author directly and refrain from direct reproduction.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT Expects Around 2% Revenue and Operating Profit Growth in FY25
BAT Expects Around 2% Revenue and Operating Profit Growth in FY25
British American Tobacco (BAT) reaffirmed its 2026 guidance while announcing a £1.3 billion (approximately USD 1.65 billion) share buyback for FY26. The company expects around 2% growth in revenue and adjusted profit from operations for FY25. Accelerating New Category growth, driven by Velo Plus and improving U.S. Vuse performance, is expected to deliver double-digit H2 revenue growth.
Dec.09 by 2FIRSTS.ai
 Breaking News | FDA Adds on! Plus Nicotine Pouches to PMTA-Authorized List
Breaking News | FDA Adds on! Plus Nicotine Pouches to PMTA-Authorized List
The U.S. Food and Drug Administration (FDA) has added ON! Plus nicotine pouch products to its list of authorized products, disclosing that the brand has received Marketing Granted Orders (MGO) through the Premarket Tobacco Product Application (PMTA) pathway. The update makes on! Plus the second nicotine pouch brand authorized via PMTA, following ZYN. As of publication, the FDA had not issued a separate press release on the decision.
News
Dec.20
UPC Court of Appeal refuses to revive VMR’s European vape patent, upholding lack of inventiveness
UPC Court of Appeal refuses to revive VMR’s European vape patent, upholding lack of inventiveness
The Unified Patent Court’s Court of Appeal declined on Dec. 29 to revive a European patent held by VMR Products LLC, upholding a finding that the patent is not inventive over earlier devices. The decision said adding a window in the vape’s outer shell to reveal the internal cartridge holding vape liquid was an obvious, routine adaptation based on an earlier U.S. patent and general knowledge.
Jan.06 by 2FIRSTS.ai
GEEKBAR Announces Restock on Social Media, Pulse and Pulse X Lines Back in Stock
GEEKBAR Announces Restock on Social Media, Pulse and Pulse X Lines Back in Stock
GEEKBAR has announced a new round of restocking across multiple overseas social media platforms, bringing its flagship Pulse and Pulse X product lines back on sale, with several previously hard-to-find flavors returning simultaneously, alongside the launch of the new Thermal Edition.
Dec.17 by 2FIRSTS.ai
Australia: NSW police and ABF seize illicit tobacco and vapes worth over A$1.6 million in Sydney’s southwest
Australia: NSW police and ABF seize illicit tobacco and vapes worth over A$1.6 million in Sydney’s southwest
In Australia’s New South Wales, a joint operation in Sydney’s southwest led to the seizure of illicit tobacco and vape products valued at over A$1.6 million (about US$1.09 million) from a warehouse in Riverwood.
Jan.22 by 2FIRSTS.ai
Philippine FDA Requires Licenses for Vape Products with Medical Claims
Philippine FDA Requires Licenses for Vape Products with Medical Claims
The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.
Dec.22 by 2FIRSTS.ai